G
Grigoris T. Gerotziafas
Researcher at University of Paris
Publications - 112
Citations - 4854
Grigoris T. Gerotziafas is an academic researcher from University of Paris. The author has contributed to research in topics: Medicine & Tissue factor. The author has an hindex of 31, co-authored 95 publications receiving 3780 citations. Previous affiliations of Grigoris T. Gerotziafas include Alexandra Hospital & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Hematological findings and complications of COVID-19.
Evangelos Terpos,Ioannis Ntanasis-Stathopoulos,Ismail Elalamy,Efstathios Kastritis,Theodoros N. Sergentanis,Marianna Politou,Theodora Psaltopoulou,Grigoris T. Gerotziafas,Meletios A. Dimopoulos +8 more
TL;DR: COVID‐19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended.
Journal ArticleDOI
Prevention and Treatment of Venous Thromboembolism: International Consensus Statement (Guidelines according to scientific evidence)
Andrew N. Nicolaides,Jawed Fareed,Ajay K. Kakkar,Anthony J. Comerota,Samuel Z. Goldhaber,R D Hull,Kenneth A. Myers,M.M. Samama,John P. Fletcher,Evi Kalodiki,David Bergqvist,J. Bonnar,Joseph A. Caprini,Charles A. Carter,J. Conard,Bo Eklof,Ismail Elalamy,Grigoris T. Gerotziafas,George Geroulakos,Athanasios D. Giannoukas,Ian A. Greer,M. Griffin,Stavros K. Kakkos,M. R. Lassen,Gordon D.O. Lowe,A. Markel,Paolo Prandoni,Gary E. Raskob,Alex C. Spyropoulos,Alexander G.G. Turpie,Jeanine M. Walenga,David Warwick +31 more
TL;DR: All patients at moderate to high risk for the development of venous thrombo- embolism should receive prophylaxis, and the approaches of proven value include low-dose heparin, low molecular weight heparins, oral anticoagulants and intermittent pneumatic compression.
Journal Article
Prevention And Treatment Of Venous Thromboembolism : International Consensus Statement
Andrew N. Nicolaides,Jawed Fareed,Ajay K. Kakkar,Anthony J. Comerota,Samuel Z. Goldhaber,Russell D. Hull,Kenneth Myers,M. M. Samama,John P. Fletcher,Evi Kalodiki,David Bergqvist,J. Bonnar,Joseph A. Caprini,Cedric J. Carter,J. Conard,Bo Eklof,Ismail Elalamy,Grigoris T. Gerotziafas,George Geroulakos,Athanasios D. Giannoukas,Ian A. Greer,Maura Griffin,Stavros K. Kakkos,M. R. Lassen,Gordon D.O. Lowe,A. Markel,Paolo Prandoni,Gary E. Raskob,Alex C. Spyropoulos,Alexander G.G. Turpie,Jeanine M. Walenga,David Warwick +31 more
TL;DR: The aim of this document is to provide a clear and concise account of the evidence regarding efficacy or harm for various methods available to prevent and manage venous thromboembolism (VTE).
Journal ArticleDOI
Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux)
TL;DR: Fondaparinux (Arixtra) as mentioned in this paper is the first of a new class of selective indirect antithrombin-dependent factor Xa inhibitors, which inhibits thrombin generation.
Journal ArticleDOI
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban
TL;DR: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.